MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
MannKind CEO, Michael Castagna, was recently interviewed on SiriusXM Business Radio Powered by The Wharton School. The show has shared the audio file of the 25-minute interview about Afrezza. Find it here
|Mar 01, 2018||MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension… More|
|Feb 27, 2018||MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results… More|
|Feb 06, 2018||David Kendall Joins MannKind as Chief Medical Officer… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.